These findings demonstrate that AKBA directly binds to MGLL and reduces its enzymatic activity, providing further evidence that AKBA may exert its therapeutic effects in metabolic disorders through the modulation of MGLL activity. This evidence concerns the gene MGLL and metabolic disease.